Zomedica (ZOM) 10-Q 12 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Document Information [Line Items]
Entity Registrant Name	Zomedica Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		974,350,084
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Shares, without par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 276,601,860	$ 61,991,703
Inventory	309,658
Prepaid expenses and deposits	1,393,616	1,727,814
Trade receivables	8,535
Other receivables	235,905	146,207
Total current assets	278,549,574	63,865,724
Prepaid expenses and deposits	39,101	13,924
Property and equipment, net	293,516	583,007
Right-of-use asset	1,263,061	1,318,716
Intangible assets, net	323,471	362,663
Total assets	280,468,723	66,144,034
Current liabilities
Accounts payable and accrued liabilities	1,128,233	1,248,628
Current portion of debt obligations	527,360	527,360
Current portion of lease liabilities	306,770	252,788
Total current liabilities	1,962,363	2,028,776
Lease obligations	978,470	1,087,998
Total liabilities	2,940,833	3,116,774
Commitments and contingencies (Note 13)
Mezzanine equity:
Series 1 preferred shares, no par value; 20 shares authorized 0 and 12 Series 1 preferred shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		11,961,397
Shareholders' equity
Unlimited common shares, no par value; 972,092,308 and 642,036,228 issued and outstanding at March 31, 2021 and December 31, 2020, respectively	377,970,846	104,783,612
Common shares subscribed	459,600	459,600
Additional paid-in capital	4,602,089	14,792,276
Accumulated deficit	(105,045,045)	(68,969,625)
Total shareholders' equity	277,527,890	51,065,863
Total liabilities, mezzanine equity and shareholders' equity	$ 280,468,723	$ 66,144,034

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	Mar. 31, 2021	Dec. 31, 2020
Mezzanine equity, par value (in dollars per share)	$ 0	$ 0
Mezzanine equity, shares authorized (in shares)	20	20
Mezzanine equity, shares issued (in shares)	0	12
Mezzanine equity, shares outstanding (in shares)	0	12
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, issued (in shares)	972,092,308	642,036,228
Capital stock, outstanding (in shares)	972,092,308	642,036,228

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenue	$ 14,124
Cost of revenue	5,658
Gross profit	8,466
Expenses
Research and development	413,128	630,066
Selling, general and administrative	3,467,670	1,703,443
Loss from operations	(3,872,332)	(2,333,509)
Interest income	(55,147)
Interest expense		651
Loss on disposal of assets	218,986	128,931
Other income		(5,500)
Foreign exchange loss (gain)	646	(6,973)
Loss before income taxes	(4,036,817)	(2,450,618)
Income tax expense
Net loss and comprehensive loss	$ (4,036,817)	$ (2,450,618)
Weighted average number of common shares - basic and diluted (in shares)	890,245,654	118,340,596
Loss per share - basic and diluted (Note 18) (in dollars per share)	$ (0.04)	$ (0.02)

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	12	108,038,398
Balance at Dec. 31, 2019	$ 11,961,397	$ 38,566,820			$ 3,625,083	$ (52,057,841)	$ 2,095,459
Stock and warrant issuance for financing (in shares)		20,833,334
Stock and warrant issuance for financing		$ 1,705,655			794,345		2,500,000
Stock issuance costs		(238,217)			(110,003)		(348,220)
Placement agent warrants		(35,816)			35,816
Stock-based compensation					155,022		155,022
Net loss						(2,450,618)	(2,450,618)
Balance (in shares) at Mar. 31, 2020	12	128,871,732
Balance at Mar. 31, 2020	$ 11,961,397	$ 39,998,442			4,500,263	(54,508,459)	1,951,643
Balance (in shares) at Dec. 31, 2020	12	642,036,228
Balance at Dec. 31, 2020	$ 11,961,397	$ 104,783,612		459,600	14,792,276	(68,969,625)	51,065,863
Stock and warrant issuance for financing (in shares)		105,013,158
Stock and warrant issuance for financing		$ 199,525,000					199,525,000
Stock issuance costs		(14,281,368)					(14,281,368)
Stock-based compensation					1,282,741		1,282,741
Net loss						(4,036,817)	(4,036,817)
Stock issuance from warrant exercises (in shares)		200,323,821	[1]
Stock issuance from warrant exercises		$ 43,943,602	[1]	459,600	(11,472,928)		32,011,074
Stock redemption (in shares)	(12)
Stock redemption	$ (11,961,397)
Stock redemption (in shares)		24,719,101
Stock redemption		$ 44,000,000				(32,038,603)	11,961,397
Balance (in shares) at Mar. 31, 2021		972,092,308
Balance at Mar. 31, 2021		$ 377,970,846			$ 4,602,089	$ (105,045,045)	$ 277,527,890
[1]	For the three months ended warrant exercises were as follows: Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 3,037,167 455,576 Series C 37,566,195 5,646,929 Series D 138,043,375 22,074,940 Subtotal 200,323,821 32,470,674 Common stock subscribed - (459,600 ) Total 200,323,821 $ 32,011,074

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (4,036,817)	$ (2,450,618)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	(59,326)	(76,416)
Amortization - intangible assets	44,321	45,036
Amortization - right-of-use asset		42,448
Loss on sale of property and equipment	243,061	69,834
(Gain) loss on right-of-use assets	(24,075)	59,097
Stock-based compensation	1,282,741	155,022
Non cash portion of rent expense	24,185	4,012
Change in non-cash operating working capital
Purchased Inventory	(309,658)
Prepaid expenses and deposits	309,021	409,028
Trade receivable	(8,535)
Other receivable	(101,508)	(74,845)
Accounts payable and accrued liabilities	(120,395)	(508,557)
Net cash used in operating activities	(2,638,333)	(2,173,127)
Cash flows from investing activities:
Cash received from sale of property and equipment	75	5,400
Investment in intangibles	(3,185)
Investment in property and equipment	(14,916)
Cash from lease cancellation		1,002,113
Net cash (used in) provided by investing activities	(18,026)	1,007,513
Cash flows from financing activities:
Cash proceeds from issuance of common shares and warrants	199,525,000	2,500,000
Cash received from warrant exercises	32,011,074
Cash paid for shares and warrant issuance costs	(14,269,558)	(348,220)
Net cash provided by financing activities	217,266,516	2,151,780
Increase in cash and cash equivalents	214,610,157	986,166
Cash and cash equivalents, beginning of year	61,991,703	510,586
Cash and cash equivalents, end of year	276,601,860	1,496,752
Supplemental cash flow information:
Interest paid		651
Interest (received)	$ (24,313)

Note 1 - Nature of Operations

Note 1 - Nature of Operations	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Nature of operations The Company is a veterinary health company creating point-of-care diagnostics products for dogs and cats, that focuses on the needs of the veterinarians themselves. The impact of the novel strain of coronavirus (“COVID- 19” The outbreak of the novel strain of coronavirus, specifically identified as “COVID- 19”, March 2020. The COVID- 19 five five may 19 may 19,

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the presentation of interim financial statements and with the instructions to Form 10 10 X. not three March 31, 2021 not may December 31, 2021. 2; 10 December 31, 2020. December 31, 2020

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not may may may Inventories Inventories are stated at the lower of cost or net realizable value. Cost is based on the first first not Revenue recognition The Company enters into agreements which may The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognize revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales tax is charged on sales to end users, and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value, and have payment terms of 30 Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold. Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no three March 31, 2020. not

Note 4 - Prepaid Expenses, Depo

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Prepaid Rent [Text Block]	4. Prepaid expenses, deposits and deferred financing costs March 31, December 31, 2021 2020 Deposits (i) $ 1,148,755 $ 1,455,119 Prepaid marketing 15,444 26,330 Prepaid insurance 109,440 184,154 Other (ii) 159,078 62,211 Total $ 1,432,717 $ 1,727,814 (i) Deposits include payments made to vendors in advance and are primarily associated with inventory, warranties, and research activity. As of March 31, 2021, December 31, 2020, $39,101 $13,924 (ii) Other is comprised of deferred financing costs, subscription payments, utilities, travel costs, and software licensing. As of March 31, 2021, December 31, 2020,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment March 31, December 31, 2021 2020 Computer equipment $ 387,055 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 220,372 234,087 Leasehold improvements 272,194 571,460 989,865 1,290,993 Accumulated depreciation and amortization 696,349 707,986 Net property and equipment $ 293,516 $ 583,007 Depreciation expense for the three March 31, 2021 $59,326.

Note 6 - Intangible Assets

Note 6 - Intangible Assets	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	6. Intangible assets March 31, December 31, 2021 2020 Computer software $ 28,011 $ 22,882 Trademarks 16,236 16,236 Website 513,680 513,680 557,927 552,798 Accumulated amortization 234,456 190,135 Net intangibles $ 323,471 $ 362,663 Amortization expense for the three March 31, 2021 $44,321.

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Leases On February 1, 2020 60 February 1, 2020 January 31, 2025 $32,452 $36,525 $1,002,113. $1,061,210 $59,097 On February 1, 2020, $1,553,611 12%. On February 1, 2021 48 February 1, 2021 January 31, 2025 $12,039 first two $30,911 $1,297,666 $24,075 On February 1, 2021, $1,306,082 3.95%. During the three March 31, 2021, $80,714 $18,626 $62,088 Right-of-use asset Premise lease Cost Aggregate lease commitments $ 1,387,655 Less: impact of present value (81,573 ) Balance at March 31, 2021 1,306,082 Reduction in right-of-use asset Straight line amortization 46,256 Interest (3,235 ) Balance at March 31, 2021 43,021 Net book value as at: March 31, 2021 $ 1,263,061 Lease liabilities Premise lease Additions $ 1,306,082 Payments (24,077 ) Interest 3,235 Total lease liabilities at March 31, 2021 1,285,240 Current portion of lease liabilities 306,770 Long term portion of lease liabilities 978,470 Total lease liabilities at March 31, 2021 $ 1,285,240 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2021 - remainder balance $ 254,591 2022 348,790 2023 359,254 2024 370,031 2025 30,911 Total $ 1,363,577

Note 8 - Loan Arrangements

Note 8 - Loan Arrangements	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Loan arrangements On October 18, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% March 31, 2021, no The Coronavirus Aid, Relief, and Economic Security Act, or (“CARES”) Act, was signed into law on March 27, 2020, $2.0 19 100% $10 2.5x not Under the Program, the borrower is eligible for loan forgiveness up to the amount the borrower spends on certain eligible costs during the 8 25% not 1% 18 24 54 24 In April 2020, $527,360

Note 9 - Preferred Stock

Note 9 - Preferred Stock	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	9. Preferred shares The Company is authorized to issue up to 20 1 $1,000,000. 1 not not 1 not 9 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which the shareholders do not 50% may third 1 1 1 5.0 9.0 Issued and outstanding preferred stock: Number of preferred Preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock redemption (12 ) (11,961,397 ) Balance at March 31, 2021 - $ - The Company exchanged the issued and outstanding shares of its Series 1 March 7, 2021 24,719,101 $44,000,000.

Note 10 - Common Stock

Note 10 - Common Stock	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Common shares The Company is authorized to issue an unlimited number of common shares, without par value. Issued and outstanding common shares: Number of Common stock Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (i) 20,833,334 1,431,622 Balance at March 31, 2020 128,871,732 $ 39,998,442 Balance at December 31, 2020 642,036,228 $ 104,783,612 Stock issued from financing (ii) 105,013,158 185,243,632 Stock issued from exercises of warrants (iii) 200,323,821 43,943,602 Stock issued from preferred share redemption (Note 10) 24,719,101 44,000,000 Balance at March 31, 2021 972,092,308 $ 377,970,846 (i) On February 14, 2020, one one 20,833,334 20,833,334 $0.12 $0.20 six 5.5 1,041,667 $0.15 5 20,833,334 20,833,334 1,041,667 The Company raised $2,500,000 $1,705,655 $794,345 The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 $348,220. $238,217 $110,003 $52,496 $35,816 $16,680 (ii) On February 8, 2021, 91,315,790 $1.90 30 13,697,368 The Company raised $199,525,000 $199,525,000 The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 $14,281,368. (iii) For the three Warrant series Warrants Amount Series A 21,677,084 $ 4,293,229 Series B 3,037,167 455,576 Series C 37,566,195 5,646,929 Series D 138,043,375 22,074,940 Subtotal 200,323,821 32,470,674 Common stock subscribed - (459,600 ) Total 200,323,821 $ 32,011,074

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. Stock-based compensation During the three March 31, 2021, 1,400,000 four ten three March 31, 2021, no three March 31, 2020, 5,056,000 four five The continuity of stock options are as follows: Number of Weighted Avg Balance at December 31, 2020 39,604,515 $ 0.36 Stock options forfeited (3,965,265 ) $ 1.52 Stock options forfeited (18,750 ) $ 0.19 Stock options granted 800,000 $ 1.87 Stock options granted 200,000 $ 2.06 Stock options granted 200,000 $ 1.88 Stock options granted 200,000 $ 2.49 Balance at March 31, 2021 37,020,500 $ 0.30 Vested at March 31, 2021 11,916,500 $ 0.29 As at March 31, 2021, Grant date Exercise Number of Number of Number of Weighted Avg August 19, 2019 0.26 500,000 500,000 - 0.39 August 19, 2019 0.35 100,000 100,000 - 0.39 August 19, 2019 0.45 100,000 100,000 - 0.39 August 19, 2019 0.55 100,000 100,000 - 0.39 August 19, 2019 0.65 100,000 100,000 - 0.39 August 19, 2019 0.75 100,000 100,000 - 0.39 September 16, 2019 0.43 500,000 500,000 - 0.46 March 14, 2020 0.19 3,705,500 1,852,750 1,852,750 3.96 June 16, 2020 0.19 2,000,000 2,000,000 - 4.21 July 9, 2020 0.18 175,000 43,750 131,250 4.28 August 25, 2020 0.13 40,000 10,000 30,000 4.41 September 29, 2020 0.11 300,000 75,000 225,000 4.50 October 1, 2020 0.11 300,000 75,000 225,000 4.51 October 20, 2020 0.09 40,000 10,000 30,000 4.56 December 31, 2020 0.23 27,560,000 6,000,000 21,560,000 9.76 February 26, 2021 1.87 800,000 200,000 600,000 9.92 March 1, 2021 2.06 200,000 50,000 150,000 9.92 March 8, 2021 1.88 200,000 50,000 150,000 9.94 March 15, 2021 2.49 200,000 50,000 150,000 9.96 Balance at March 31, 2021 37,020,500 11,916,500 25,104,000 11. Stock-based compensation (continued) The Company calculates volatility of stock-based compensation using the historical price of the Company's stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The fair value of options granted during the three March 31, 2021 March 31, 2020 March 14, 2020 February 26, 2021 Volatility 87 % 117 % Risk-free interest rate 0.49 % 0.95 % Expected life (in years) 5 10 Dividend yield 0 % 0 % Common share price $ 0.18 $ 1.87 Strike price $ 0.19 $ 1.87 Forfeiture rate 0 0 March 1, 2021 March 8, 2021 Volatility 117 % 117 % Risk-free interest rate 0.92 % 1.07 % Expected life (in years) 10 10 Dividend yield 0 % 0 % Common share price $ 2.06 $ 1.88 Strike price $ 2.06 $ 1.88 Forfeiture rate 0 0 March 15, 2021 Volatility 117 % Risk-free interest rate 1.06 % Expected life (in years) 10 Dividend yield 0 % Common share price $ 2.49 Strike price $ 2.49 Forfeiture rate 0 The Company recorded $1,282,741 $155,022 three March 31, 2021 2020, three March 31, 2021 2020 no

Note 12 - Warrants

Note 12 - Warrants	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Warrants Note Disclosure [Text Block]	12. Warrants The Company calculates volatility of warrants based on the historical price of the Company's stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. In connection with the February 14, 2020 20,833,334 five one one $.20. 1,041,667 $0.15 In connection with the April 9, 2020 16,666,667 five one $0.15. 1,666,667 one $0.15 In connection with the May 29, 2020 133,333,333 two one $0.15. 12,170,000 $0.0001 December 31, 2020, In connection with the July 7, 2020 187,500,000 two one $0.16. 25,000,000 $0.0001 December 31, 2020, As at March 31, 2021, Original Issue date Exercise Warrants Weighted Average February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.87 April 9, 2020 0.15 366,585 4.03 May 29, 2020 0.15 276,500 1.16 July 7, 2020 0.16 856,000 1.27 Balance at March 31, 2021 1,697,002

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and contingencies On May 10, 2018, • 1 st $3,500,000 • 2 nd $3,500,000 10 As at March 31, 2021, none not March 31, 2021. From time to time, the Company may March 31, 2021, May 12, 2021, not On November 1, 2019, 1:19 01108 November 22, 2019. January 21, 2020, February 11, 2020, February 25, 2020. September 30, 2020, October 14, 2020 May 10, 2021, no not Under the terms of the Development and Supply Agreement, dated November 26, 2018, third

Note 14 - Financial Instruments

Note 14 - Financial Instruments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	14. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at March 31, 2021 December 31, 2020: March 31, 2021 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,128,233 $ - $ - $ - $ - $ 1,128,233 Debt obligations 527,360 - - - - 527,360 Lease obligations 75,413 75,980 76,551 78,826 978,470 1,285,240 $ 1,731,006 $ 75,980 $ 76,551 $ 78,826 $ 978,470 $ 2,940,833 December 31, 2020 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segmented Information

Note 15 - Segmented Information	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Segment information The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion animal. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all the Company's long-lived assets are in the United States of America (“US”). March 31, December 31, 2021 2020 Canada $ 250,972,315 $ 53,160,701 US 29,496,408 12,983,333 Total assets $ 280,468,723 $ 66,144,034 Total US property and equipment $ 293,516 $ 583,007 Total US right-of-use asset 1,263,062 1,318,716 $ 1,556,578 $ 1,901,723

Note 16 - Loss Per Share

Note 16 - Loss Per Share	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	16. Loss per share For the three months For the three months Numerator Net loss for the period $ (4,036,817 ) $ (2,450,618 ) Charge to retained earnings for preferred share exchange (32,038,603 ) - Loss attributable to common shareholders (36,075,420 ) (2,450,618 ) Denominator Weighted average shares - basic 890,245,654 118,340,596 Stock options - - Warrants - - Denominator for diluted loss per share 890,245,654 118,340,596 Loss per share - basic and diluted $ (0.04 ) $ (0.02 ) For the above-mentioned periods, the Company had stock options and warrants outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not may may may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is based on the first first not
Revenue [Policy Text Block]	Revenue recognition The Company enters into agreements which may The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognize revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales tax is charged on sales to end users, and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value, and have payment terms of 30
Cost of Goods and Service [Policy Text Block]	Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold.
Reclassification, Comparability Adjustment [Policy Text Block]	Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no three March 31, 2020. not

Note 4 - Prepaid Expenses, De_2

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	March 31, December 31, 2021 2020 Deposits (i) $ 1,148,755 $ 1,455,119 Prepaid marketing 15,444 26,330 Prepaid insurance 109,440 184,154 Other (ii) 159,078 62,211 Total $ 1,432,717 $ 1,727,814

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2021 2020 Computer equipment $ 387,055 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 220,372 234,087 Leasehold improvements 272,194 571,460 989,865 1,290,993 Accumulated depreciation and amortization 696,349 707,986 Net property and equipment $ 293,516 $ 583,007

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, December 31, 2021 2020 Computer software $ 28,011 $ 22,882 Trademarks 16,236 16,236 Website 513,680 513,680 557,927 552,798 Accumulated amortization 234,456 190,135 Net intangibles $ 323,471 $ 362,663

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities [Table Text Block]	Right-of-use asset Premise lease Cost Aggregate lease commitments $ 1,387,655 Less: impact of present value (81,573 ) Balance at March 31, 2021 1,306,082 Reduction in right-of-use asset Straight line amortization 46,256 Interest (3,235 ) Balance at March 31, 2021 43,021 Net book value as at: March 31, 2021 $ 1,263,061 Lease liabilities Premise lease Additions $ 1,306,082 Payments (24,077 ) Interest 3,235 Total lease liabilities at March 31, 2021 1,285,240 Current portion of lease liabilities 306,770 Long term portion of lease liabilities 978,470 Total lease liabilities at March 31, 2021 $ 1,285,240
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 - remainder balance $ 254,591 2022 348,790 2023 359,254 2024 370,031 2025 30,911 Total $ 1,363,577

Note 9 - Preferred Stock (Table

Note 9 - Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of preferred Preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock redemption (12 ) (11,961,397 ) Balance at March 31, 2021 - $ -

Note 10 - Common Stock (Tables)

Note 10 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of Common stock Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (i) 20,833,334 1,431,622 Balance at March 31, 2020 128,871,732 $ 39,998,442 Balance at December 31, 2020 642,036,228 $ 104,783,612 Stock issued from financing (ii) 105,013,158 185,243,632 Stock issued from exercises of warrants (iii) 200,323,821 43,943,602 Stock issued from preferred share redemption (Note 10) 24,719,101 44,000,000 Balance at March 31, 2021 972,092,308 $ 377,970,846
Class of Warrant or Right, Warrant Series [Table Text Block]	Warrant series Warrants Amount Series A 21,677,084 $ 4,293,229 Series B 3,037,167 455,576 Series C 37,566,195 5,646,929 Series D 138,043,375 22,074,940 Subtotal 200,323,821 32,470,674 Common stock subscribed - (459,600 ) Total 200,323,821 $ 32,011,074

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Avg Balance at December 31, 2020 39,604,515 $ 0.36 Stock options forfeited (3,965,265 ) $ 1.52 Stock options forfeited (18,750 ) $ 0.19 Stock options granted 800,000 $ 1.87 Stock options granted 200,000 $ 2.06 Stock options granted 200,000 $ 1.88 Stock options granted 200,000 $ 2.49 Balance at March 31, 2021 37,020,500 $ 0.30 Vested at March 31, 2021 11,916,500 $ 0.29
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise Number of Number of Number of Weighted Avg August 19, 2019 0.26 500,000 500,000 - 0.39 August 19, 2019 0.35 100,000 100,000 - 0.39 August 19, 2019 0.45 100,000 100,000 - 0.39 August 19, 2019 0.55 100,000 100,000 - 0.39 August 19, 2019 0.65 100,000 100,000 - 0.39 August 19, 2019 0.75 100,000 100,000 - 0.39 September 16, 2019 0.43 500,000 500,000 - 0.46 March 14, 2020 0.19 3,705,500 1,852,750 1,852,750 3.96 June 16, 2020 0.19 2,000,000 2,000,000 - 4.21 July 9, 2020 0.18 175,000 43,750 131,250 4.28 August 25, 2020 0.13 40,000 10,000 30,000 4.41 September 29, 2020 0.11 300,000 75,000 225,000 4.50 October 1, 2020 0.11 300,000 75,000 225,000 4.51 October 20, 2020 0.09 40,000 10,000 30,000 4.56 December 31, 2020 0.23 27,560,000 6,000,000 21,560,000 9.76 February 26, 2021 1.87 800,000 200,000 600,000 9.92 March 1, 2021 2.06 200,000 50,000 150,000 9.92 March 8, 2021 1.88 200,000 50,000 150,000 9.94 March 15, 2021 2.49 200,000 50,000 150,000 9.96 Balance at March 31, 2021 37,020,500 11,916,500 25,104,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 14, 2020 February 26, 2021 Volatility 87 % 117 % Risk-free interest rate 0.49 % 0.95 % Expected life (in years) 5 10 Dividend yield 0 % 0 % Common share price $ 0.18 $ 1.87 Strike price $ 0.19 $ 1.87 Forfeiture rate 0 0 March 1, 2021 March 8, 2021 Volatility 117 % 117 % Risk-free interest rate 0.92 % 1.07 % Expected life (in years) 10 10 Dividend yield 0 % 0 % Common share price $ 2.06 $ 1.88 Strike price $ 2.06 $ 1.88 Forfeiture rate 0 0 March 15, 2021 Volatility 117 % Risk-free interest rate 1.06 % Expected life (in years) 10 Dividend yield 0 % Common share price $ 2.49 Strike price $ 2.49 Forfeiture rate 0

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Original Issue date Exercise Warrants Weighted Average February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.87 April 9, 2020 0.15 366,585 4.03 May 29, 2020 0.15 276,500 1.16 July 7, 2020 0.16 856,000 1.27 Balance at March 31, 2021 1,697,002

Note 14 - Financial Instrumen_2

Note 14 - Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	March 31, 2021 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,128,233 $ - $ - $ - $ - $ 1,128,233 Debt obligations 527,360 - - - - 527,360 Lease obligations 75,413 75,980 76,551 78,826 978,470 1,285,240 $ 1,731,006 $ 75,980 $ 76,551 $ 78,826 $ 978,470 $ 2,940,833 December 31, 2020 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segmented Informati_2

Note 15 - Segmented Information (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	March 31, December 31, 2021 2020 Canada $ 250,972,315 $ 53,160,701 US 29,496,408 12,983,333 Total assets $ 280,468,723 $ 66,144,034 Total US property and equipment $ 293,516 $ 583,007 Total US right-of-use asset 1,263,062 1,318,716 $ 1,556,578 $ 1,901,723

Note 16 - Loss Per Share (Table

Note 16 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months For the three months Numerator Net loss for the period $ (4,036,817 ) $ (2,450,618 ) Charge to retained earnings for preferred share exchange (32,038,603 ) - Loss attributable to common shareholders (36,075,420 ) (2,450,618 ) Denominator Weighted average shares - basic 890,245,654 118,340,596 Stock options - - Warrants - - Denominator for diluted loss per share 890,245,654 118,340,596 Loss per share - basic and diluted $ (0.04 ) $ (0.02 )

Note 4 - Prepaid Expenses, De_3

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs (Details Textual) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Deposits, Noncurrent	$ 39,101	$ 13,924

Note 4 - Prepaid Expenses, De_4

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs - Summary of Prepaid Expenses, Deposits and Deferred Financing Costs (Details) - USD ($)		Mar. 31, 2021	Dec. 31, 2020
Deposits	[1]	$ 1,148,755	$ 1,455,119
Prepaid marketing		15,444	26,330
Prepaid insurance		109,440	184,154
Other	[2]	159,078	62,211
Total		$ 1,432,717	$ 1,727,814
[1]	Deposits include payments made to vendors in advance and are primarily associated with inventory and research activity. As of March 31, 2021, and December 31, 2020, the Company classified $39,101 and $13,924 as a non-current asset, with the remainder classified as a current asset in the consolidated balance sheets
[2]	Other is comprised of deferred financing costs, subscription payments, utilities, travel costs, warranties, and software licensing. As of March 31, 2021, and December 31, 2020, the Company classified all amounts as a current asset in the consolidated balance sheets.

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Total	$ 59,326	$ 76,416

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 989,865	$ 1,290,993
Accumulated depreciation and amortization	696,349	707,986
Net property and equipment	293,516	583,007
Computer Equipment [Member]
Property and equipment, gross	387,055	364,165
Furniture and Fixtures [Member]
Property and equipment, gross	110,244	121,281
Laboratory Equipment [Member]
Property and equipment, gross	220,372	234,087
Leasehold Improvements [Member]
Property and equipment, gross	$ 272,194	$ 571,460

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization of Intangible Assets, Total	$ 44,321	$ 45,036

Note 6 - Intangible Assets - Fi

Note 6 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Finite-lived intangible assets, gross	$ 557,927	$ 552,798
Accumulated amortization	234,456	190,135
Net intangibles	323,471	362,663
Computer Software, Intangible Asset [Member]
Finite-lived intangible assets, gross	28,011	22,882
Trademarks [Member]
Finite-lived intangible assets, gross	16,236	16,236
Website [Member]
Finite-lived intangible assets, gross	$ 513,680	$ 513,680

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	Feb. 01, 2021	Feb. 01, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Increase (Decrease) in Prepaid Rent				$ 1,002,113
Gain (loss) on Operating Lease, Right-of-Use Assets			24,075	$ (59,097)
Operating Lease, Right-of-Use Asset			1,263,061		$ 1,318,716
Operating Lease, Liability, Total			1,285,240		$ 1,340,786
Lease Agreement with Wickfield Phoenix LLC [Member]
Lessee, Operating Lease, Term of Contract (Month)	4 years	5 years
Monthly Rent Payment		$ 36,525
Gain (loss) on Operating Lease, Right-of-Use Assets	$ 24,075
Operating Lease, Right-of-Use Asset	$ 1,306,082	$ 1,553,611
Lessee, Operating Lease, Discount Rate	3.95%	12.00%
Operating Lease, Right-of-Use Asset, Lease Modification	$ 1,297,666
Operating Lease, Expense			80,714
Operating Lease, Liability, Total	1,306,082
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense			18,626
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense			$ 62,088
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	12,039	$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | Maximum [Member]
Monthly Rent Payment	$ 30,911
Lease Cancellation [Member]
Increase (Decrease) in Prepaid Rent		1,002,113
Operating Lease, Right-of-Use Asset, Lease Cancellation		1,061,210
Lease Modification [Member]
Gain (loss) on Operating Lease, Right-of-Use Assets		$ (59,097)

Note 7 - Leases - Right of Use

Note 7 - Leases - Right of Use Asset and Lease Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Aggregate lease commitments	$ 1,387,655
Less: impact of present value	(81,573)
Cost, balance	1,306,082
Straight line amortization	46,256
Interest	(3,235)
Reduction in right-of-use asset, balance	43,021
Net book value	1,263,061	$ 1,318,716
Additions	1,306,082
Payments	(24,077)
Interest	3,235
Operating Lease, Liability, Total	1,285,240	1,340,786
Current portion of lease liabilities	306,770	252,788
Long term portion of lease liabilities	$ 978,470	$ 1,087,998

Note 7 - Leases - Remaining Und

Note 7 - Leases - Remaining Undiscounted Lease Liabilities (Details)	Mar. 31, 2021USD ($)
2021 - remainder balance	$ 254,591
2022	348,790
2023	359,254
2024	370,031
2025	30,911
Total	$ 1,363,577

Note 8 - Loan Arrangements (Det

Note 8 - Loan Arrangements (Details Textual) - USD ($)	Oct. 18, 2017	Apr. 30, 2020	Mar. 31, 2021	Dec. 31, 2020
Long-term Debt, Total			$ 527,360	$ 527,360
Loan Arrangement With Shareholder [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term (Year)	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total			$ 0
Paycheck Protection Program CARES Act [Member]
Proceeds from Short-term Debt, Total		$ 527,360

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - USD ($)	Mar. 07, 2021	Mar. 31, 2021
Conversion of Stock, Amount Issued		$ 11,961,397
Redemption of Preferred Shares for Common Shares [Member]
Conversion of Stock, Shares Issued (in shares)	24,719,101
Conversion of Stock, Amount Issued	$ 44,000,000
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)		20
Preferred Stock, Stated Value Per Share (in dollars per share)		$ 1,000,000
Net Sales Payments, Percentage of Sales		9.00%

Note 9 - Preferred Stock - Issu

Note 9 - Preferred Stock - Issued and Outstanding Preferred Stock (Details) - Series 1 Preferred Shares [Member] - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance, number (in shares)	0	12	12
Balance, amount	$ 0	$ 11,961,397	$ 11,961,397
Stock redemption (in shares)	(12)
Stock redemption	$ (11,961,397)

Note 10 - Common Stock (Details

Note 10 - Common Stock (Details Textual) - USD ($)	Feb. 08, 2021	Feb. 14, 2020	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2020	Apr. 09, 2020
Issuance of Common Shares and Warrants, Direct Costs of Issuance	$ 14,281,368		$ 348,220	$ (14,281,368)	$ (348,220)
Adjustments to Equity, Warrant Issued
Proceeds from Issuance of Common Stock				199,525,000	2,500,000
Common Stock [Member]
Stock Issued During Period, Value, New Issues	$ 199,525,000
Issuance of Common Shares and Warrants, Direct Costs of Issuance			238,217	(14,281,368)	(238,217)
Adjustments to Equity, Warrant Issued					(35,816)
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance			110,003		(110,003)
Adjustments to Equity, Warrant Issued					$ 35,816
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		20,833,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20
Class of Warrant or Right, Period Exerciseable (Month)		180 days
Warrants and Rights Outstanding, Term (Year)		5 years 182 days
Class of Warrant or Right, Issued During Period (in shares)		20,833,334
Class of Warrant or Right, Issued During Period, Value		$ 794,345
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,041,667				1,666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15				$ 0.15
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Issued During Period (in shares)		1,041,667
Adjustments to Equity, Warrant Issued			52,496
Placement Agent Warrants [Member] | Common Stock [Member]
Adjustments to Equity, Warrant Issued			35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued			$ 16,680
Registered Direct Offering [Member]
Shares Issued, Number of Common Shares Per Share (in shares)		1
Stock Issued During Period, Shares, New Issues (in shares)		20,833,334
Shares Issued, Price Per Share (in dollars per share)		$ 0.12
Proceeds from Issuance or Sale of Equity, Total		$ 2,500,000
Stock Issued During Period, Value, New Issues		$ 1,705,655
The Common Shares Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	91,315,790
Shares Issued, Price Per Share (in dollars per share)	$ 1.90
Proceeds from Issuance of Common Stock	$ 199,525,000
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368

Note 10 - Common Stock - Issued

Note 10 - Common Stock - Issued and Outstanding Common Shares (Details) - USD ($)		3 Months Ended
		Mar. 31, 2021		Mar. 31, 2020
Number of common shares (in shares)		642,036,228
Stock issued from exercises of warrants (iii)		$ 32,011,074
Stock issued from preferred share redemption (Note 10)		$ 11,961,397
Number of common shares (in shares)		972,092,308
Common Stock [Member]
Number of common shares (in shares)		642,036,228		108,038,398
Capital stock		$ 104,783,612		$ 38,566,820
Stock issued from financing, net of cost (in shares)		105,013,158	[1]	20,833,334	[2]
Stock issued from financing, net of cost		$ 185,243,632	[1]	$ 1,431,622	[2]
Stock issued from exercises of warrants (iii) (in shares)	[3]	200,323,821
Stock issued from exercises of warrants (iii)	[3]	$ 43,943,602
Stock issued from preferred share redemption (Note 10) (in shares)		24,719,101
Stock issued from preferred share redemption (Note 10)		$ 44,000,000
Number of common shares (in shares)		972,092,308		128,871,732
Capital stock		$ 377,970,846		$ 39,998,442
[1]	On February 8, 2021, the Company completed a sale of 91,315,790 common shares at an offering price of $1.90 per share. The company also granted the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price. The Company raised $199,525,000 in gross proceeds as part of the offering. The Company recorded $199,525,000 as the value of common shares under common stock. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 were $14,281,367. These direct costs were recorded as an offset against the statement of shareholders' equity with the entirety recorded under capital stock.
[2]	On February 14, 2020, the Company completed a registered direct offering ("RDO") of its common shares and a simultaneous private placement of its warrants ("Series A Warrants") in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5.5 years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share ("Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common stock and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders' equity with $238,217 being recorded under capital stock and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders' equity with $35,816 being recorded under capital stock and $16,680 being recorded under additional paid-in-capital.
[3]	For the three months ended warrant exercises were as follows: Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 3,037,167 455,576 Series C 37,566,195 5,646,929 Series D 138,043,375 22,074,940 Subtotal 200,323,821 32,470,674 Common stock subscribed - (459,600 ) Total 200,323,821 $ 32,011,074

Note 10 - Common Stock - Warran

Note 10 - Common Stock - Warrant Exercises (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Class of warrant or right, warrants exercised (in shares)	200,323,821
Class of warrant or right, warrants exercised, value	$ 32,470,674
Common stock subscribed, value	(459,600)	$ (459,600)
Class of warrant or right, warrants exercised, total value	$ 32,011,074
Series A Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	21,677,084
Class of warrant or right, warrants exercised, value	$ 4,293,229
Series B Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	3,037,167
Class of warrant or right, warrants exercised, value	$ 455,576
Series C Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	37,566,195
Class of warrant or right, warrants exercised, value	$ 5,646,929
Series D Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	138,043,375
Class of warrant or right, warrants exercised, value	$ 22,074,940

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,400,000	5,056,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	0
Share-based Payment Arrangement, Expense	$ 1,282,741	$ 155,022
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised	$ 0	$ 0

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Number of Options, Options Outstanding (in shares)	37,020,500		39,604,515
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)	$ 0.30		$ 0.36
Number of Options, Options Granted (in shares)	1,400,000	5,056,000
Number of Options, Options Vested (in shares)	11,916,500
Weighted Avg Exercise Price, Vested (in dollars per share)	$ 0.29
Options 1 [Member]
Stock options forfeited (in shares)	(3,965,265)
Weighted Avg Exercise Price, Options Forfeited (in dollars per share)	$ 1.52
Options 2 [Member]
Stock options forfeited (in shares)	(18,750)
Weighted Avg Exercise Price, Options Forfeited (in dollars per share)	$ 0.19
Options 3 [Member]
Number of Options, Options Granted (in shares)	800,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.87
Options 4 [Member]
Number of Options, Options Granted (in shares)	200,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 2.06
Options 5 [Member]
Number of Options, Options Granted (in shares)	200,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.88
Options 6 [Member]
Number of Options, Options Granted (in shares)	200,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 2.49

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Number of Options, Options Outstanding (in shares)	37,020,500	39,604,515
Number of unvested options outstanding (in shares)	25,104,000
Number of Options, Options Vested (in shares)	11,916,500
Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.87
Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	2.06
August 19, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.26
Number of Options, Options Outstanding (in shares)	500,000
Number of Vested Options (in shares)	500,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
August 19, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.35
Number of Options, Options Outstanding (in shares)	100,000
Number of Vested Options (in shares)	100,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
August 19, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.45
Number of Options, Options Outstanding (in shares)	100,000
Number of Vested Options (in shares)	100,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
August 19, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.55
Number of Options, Options Outstanding (in shares)	100,000
Number of Vested Options (in shares)	100,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
August 19, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.65
Number of Options, Options Outstanding (in shares)	100,000
Number of Vested Options (in shares)	100,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
August 19, 2019 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.75
Number of Options, Options Outstanding (in shares)	100,000
Number of Vested Options (in shares)	100,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	142 days
September 16, 2019 [Member] | Option 7 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.43
Number of Options, Options Outstanding (in shares)	500,000
Number of Vested Options (in shares)	500,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	167 days
March 14, 2020 [Member] | Option 8 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.19
Number of Options, Options Outstanding (in shares)	3,705,500
Number of Vested Options (in shares)	1,852,750
Number of unvested options outstanding (in shares)	1,852,750
Weighted Avg Remaining Life (Year)	3 years 350 days
June 16, 2020 [Member] | Option 9 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.19
Number of Options, Options Outstanding (in shares)	2,000,000
Number of unvested options outstanding (in shares)
Weighted Avg Remaining Life (Year)	4 years 76 days
Number of Options, Options Vested (in shares)	2,000,000
July 9, 2020 [Member] | Option 10 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.18
Number of Options, Options Outstanding (in shares)	175,000
Number of unvested options outstanding (in shares)	131,250
Weighted Avg Remaining Life (Year)	4 years 102 days
Number of Options, Options Vested (in shares)	43,750
August 25, 2020 [Member] | Option 11 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.13
Number of Options, Options Outstanding (in shares)	40,000
Number of unvested options outstanding (in shares)	30,000
Weighted Avg Remaining Life (Year)	4 years 149 days
Number of Options, Options Vested (in shares)	10,000
September 29, 2020 [Member] | Option 12 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.11
Number of Options, Options Outstanding (in shares)	300,000
Number of unvested options outstanding (in shares)	225,000
Weighted Avg Remaining Life (Year)	4 years 182 days
Number of Options, Options Vested (in shares)	75,000
October 1, 2020 [Member] | Option 13 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.11
Number of Options, Options Outstanding (in shares)	300,000
Number of unvested options outstanding (in shares)	225,000
Weighted Avg Remaining Life (Year)	4 years 186 days
Number of Options, Options Vested (in shares)	75,000
October 20, 2020 [Member] | Option 14 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.09
Number of Options, Options Outstanding (in shares)	40,000
Number of unvested options outstanding (in shares)	30,000
Weighted Avg Remaining Life (Year)	4 years 204 days
Number of Options, Options Vested (in shares)	10,000
December 31, 2020 [Member] | Option 15 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.23
Number of Options, Options Outstanding (in shares)	27,560,000
Number of unvested options outstanding (in shares)	21,560,000
Weighted Avg Remaining Life (Year)	9 years 277 days
Number of Options, Options Vested (in shares)	6,000,000
February 26, 2021 [Member] | Options 16 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.87
Number of Options, Options Outstanding (in shares)	800,000
Number of unvested options outstanding (in shares)	600,000
Weighted Avg Remaining Life (Year)	9 years 335 days
Number of Options, Options Vested (in shares)	200,000
March 1, 2021 [Member] | Options 17 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 2.06
Number of Options, Options Outstanding (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 335 days
Number of Options, Options Vested (in shares)	50,000
March 8, 2021 [Member] | Options 18 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.88
Number of Options, Options Outstanding (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 343 days
Number of Options, Options Vested (in shares)	50,000
March 15, 2021 [Member] | Options 19 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 2.49
Number of Options, Options Outstanding (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 350 days
Number of Options, Options Vested (in shares)	50,000

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Mar. 15, 2021	Mar. 08, 2021	Mar. 01, 2021	Feb. 26, 2021	Mar. 14, 2020
Volatility	117.00%		117.00%		87.00%
Risk-free interest rate	1.06%		0.92%		0.49%
Expected life (in years) (Year)	10 years		10 years		5 years
Dividend yield	0.00%		0.00%		0.00%
Common share price (in dollars per share)	$ 2.49		$ 2.06		$ 0.18
Strike price (in dollars per share)	$ 2.49		$ 2.06		$ 0.19
Forfeiture rate	0.00%		0.00%		0.00%
Minimum [Member]
Volatility		117.00%		117.00%
Risk-free interest rate		1.07%		0.95%
Expected life (in years) (Year)		10 years		10 years
Dividend yield		0.00%		0.00%
Common share price (in dollars per share)		$ 1.88		$ 1.87
Strike price (in dollars per share)		$ 1.88		$ 1.87
Forfeiture rate		0.00%		0.00%

Note 12 - Warrants (Details Tex

Note 12 - Warrants (Details Textual) - $ / shares	Jul. 07, 2020	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Warrants and Rights Outstanding, Term (Year)				5 years 182 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667	1,041,667
Warrants and Rights Outstanding, Term (Year)				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15	$ 0.15
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		133,333,333
Warrants and Rights Outstanding, Term (Year)		2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Series C Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		12,170,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Warrants and Rights Outstanding, Term (Year)	2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.16
Series D Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	25,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001

Note 12 - Warrants - Details of

Note 12 - Warrants - Details of Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Warrants and Rights, Outstanding (in shares)	1,697,002
Warrant One [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.20
Warrants and Rights, Outstanding (in shares)
Warrants, weighted average remaining life (Year)
Warrant Two [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	197,917
Warrants, weighted average remaining life (Year)	3 years 317 days
Warrant Three [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	366,585
Warrants, weighted average remaining life (Year)	4 years 10 days
Warrant Four [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	276,500
Warrants, weighted average remaining life (Year)	1 year 58 days
Warrant Five [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.16
Warrants and Rights, Outstanding (in shares)	856,000
Warrants, weighted average remaining life (Year)	1 year 98 days

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - Seraph Biosciences, Inc. [Member]	May 10, 2018USD ($)
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash	$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity	$ 3,500,000

Note 14 - Financial Instrumen_3

Note 14 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accounts payable and Accrued Liabilities, maturity less than 3 Months	$ 1,128,233	$ 1,248,628
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities, Greater than 1 Year
Accounts payable and accrued liabilities	1,128,233	1,248,628
Debt obligations, maturity less than 3 Months	527,360	527,360
Debt obligations, Maturity 3 to 6 Months
Debt obligations, Maturity 6 to 9 Months
Debt obligations, Maturity 9 to 12 Months
Debt obligations, Maturity Greater Than 1 Year
Debt obligations	527,360	527,360
Lease obligations, maturity less than 3 Months	75,413	59,662
Lease obligations, Maturity 3 to 6 Months	75,980	62,463
Lease obligations, Maturity 6 to 9 Months	76,551	64,356
Lease obligations, Maturity 9 to 12 Months	78,826	66,307
Long term portion of lease liabilities	978,470	1,087,998
Lease obligations	1,285,240	1,340,786
Maturity Less Than 3 Months	1,731,006	1,835,650
Maturity 3 to 6 Months	75,980	62,463
Maturity 6 to 9 Months	76,551	64,356
Maturity 9 to 12 Months	78,826	66,307
Maturity Greater Than 1 Year	978,470	1,087,998
Liabilities, Total	$ 2,940,833	$ 3,116,774

Note 15 - Segmented Informati_3

Note 15 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Assets	$ 280,468,723	$ 66,144,034
Total US property and equipment	293,516	583,007
Total US right-of-use asset	1,263,061	1,318,716
Property, Plant and Equipment, Including Leased Assets	1,556,578	1,901,723
CANADA
Assets	250,972,315	53,160,701
UNITED STATES
Assets	29,496,408	12,983,333
Total US property and equipment	$ 293,516	$ 583,007

Note 16 - Loss Per Share - Loss

Note 16 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss	$ (4,036,817)	$ (2,450,618)
Charge to retained earnings for preferred share exchange	(32,038,603)
Loss attributable to common shareholders	$ (36,075,420)	$ (2,450,618)
Weighted average shares - basic (in shares)	890,245,654	118,340,596
Stock options (in shares)
Warrants (in shares)
Denominator for diluted loss per share (in shares)	890,245,654	118,340,596
Loss per share - basic and diluted (Note 18) (in dollars per share)	$ (0.04)	$ (0.02)